发明名称 |
Formulation having mobilising activity |
摘要 |
The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone. |
申请公布号 |
US8771663(B2) |
申请公布日期 |
2014.07.08 |
申请号 |
US201012755321 |
申请日期 |
2010.04.06 |
申请人 |
Gentium SPA |
发明人 |
Ferro Laura;Porta Roberto;Iacobelli Massimo;Gianni Massimo Alessandro;Stella Carmelo Carlo |
分类号 |
A61K38/19 |
主分类号 |
A61K38/19 |
代理机构 |
Perkins Coie, LLP |
代理人 |
Perkins Coie, LLP |
主权项 |
1. A formulation comprising a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and defibrotide as described in Chemical Abstract Registry No. 83712-60-1, wherein said formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone. |
地址 |
Villa Guardia IT |